Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Mirikizumab Formulations in Healthy Subjects
NCT04548219Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at Day 85, Area Under the Concentration Versus Time Curve From Time Zero to Infinity at Day 85 and 1 more. Started Sep 2020; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04548219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548219.